

DAFTAR PUSTAKA

- Adams, B. S., & Nguyen, H. 2020. Salmeterol.
- Agarwal AK, Raja A, Brown BD. Chronic Obstructive Pulmonary Disease. Updated 2023 Aug 7 In: StatPearls (Internet) Treasure Island (FL): StatPearls Publishing; 2024 Jan
- Agustí, A., & Hogg, J. C. (2019). Update on the pathogenesis of chronic obstructive pulmonary disease. *New England Journal of Medicine*, 381(13), 1248-1256.
- Alhussien, B. H., Altowijri, A., & Alhussien, S. H. 2024. Awareness and knowledge of Pharmacoeconomics among pharmacist and pharmacy students in Saudi Arabia. *International Journal of Medicine in Developing Countries*, 8(1), 253-253.
- Asyari, F.M., Aprilia, C.A. and Bahar, M., 2020. ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN ANTIBIOTIK SEFTRIAKSON DAN SEFOTAKSIM PADA PASIEN RAWAT INAP DEMAM TIFOID ANAK DI RSUD DEPOK TAHUN 2017-2018. In *Seminar Nasional Riset Kedokteran* (Vol. 1, No. 1).Aulia, D., Ayu, S.F. and Nefonafratilova, N., 2017. Analisis Perbandingan Biaya Langsung (Direct Cost) dan Biaya Tidak Langsung (Indirect Cost) pada Pasien Stroke Di Rumah Sakit. *Jurnal Ekonomi Kesehatan Indonesia*, 2(2).
- [Balitbangkes] Badan Penelitian dan Pengembangan Kesehatan. 2013. Riset Kesehatan Dasar (RISKESDAS) 2013. *Laporan Nasional*.
- Bang, H., & Zhao, H. 2014. Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis. *Journal of biopharmaceutical statistics*, 24(2), 443-460.
- Barisione, G. and Brusasco, V., 2023. Reply to: Lung pathophysiology in patients with long COVID-19: one size definitely does not fit all. *ERJ Open Research*, 9(4).
- Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Beta-2 Adrenergic Agonists. (Updated 2017 Sep 11). *LiverTox: Clinical and Research Information on Drug-Induced Liver Injury*.
- Boers, E., Barrett, M., Su, J.G., Benjafield, A.V., Sinha, S., Kaye, L., Zar, H.J., Vuong, V., Tellez, D., Gondalia, R. and Rice, M.B., 2023. Global burden of chronic obstructive pulmonary disease through 2050. *JAMA Network Open*, 6(12), pp.e2346598-e2346598.
- Centers for Disease Control and Prevention 2022. National Trends 2022. Diakses melalui : <https://www.cdc.gov/copd/data-and-statistics/national-trends.html>

- Cho, S. H., Lin, H. C., Ghoshal, A. G., Bin Abdul Muttalif, A. R., Thanaviratananich, S., Bagga, S., ... & Wang, D. Y. 2016, March. Respiratory disease in the Asia-Pacific region: Cough as a key symptom. In *Allergy & Asthma Proceedings* (Vol. 37, No. 2).
- David, S. and Edwards, C.W., 2019. Forced expiratory volume. Girish, K., & Amoolya, D. 2020. A comparison of cost-effectiveness between doxycycline and azithromycin with topical clindamycin in the treatment of patients with moderate to severe acne vulgaris: Prospective, randomized study. *National Journal of Physiology, Pharmacy and Pharmacology*, 10(4), 279-284.
- Easter, M., Bollenbecker, S., Barnes, J. W., & Krick, S. 2020. Targeting aging pathways in chronic obstructive pulmonary disease. *International journal of molecular sciences*, 21(18), 6924.
- [GOLD 2023] Global Initiative For Chronic Obstructive Lung Disease 2023. GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC BSTRUCTIVE PULMONARY DISEASE. 2023 Report.
- Goërtz, Y. M., Looijmans, M., Prins, J. B., Janssen, D. J., Thong, M. S., Peters, J. B., ... & Spruit, M. A. 2018. Fatigue in patients with chronic obstructive pulmonary disease: protocol of the Dutch multicentre, longitudinal, observational FAntasTIGUE study. *BMJ open*, 8(4), e021745.
- Habbie, A., Hasbie, N. F., Oktobiannobel, J., & Soemarwoto, R. A. S. 2023. Gambaran Kepatuhan Penggunaan Inhaler Kombinasi Ics/Laba Dan Quality of Life Pada Pasien Ppok Dengan Asma Di Kabupaten Pringsewu Provinsi Lampung. *Jurnal Ilmu Kedokteran dan Kesehatan*, 10(5), 1928-1936.
- Ho, J.K., Shaker, M., Greenhawt, M., Sadatsafavi, M., Abrams, E.M., Oppenheimer, J., Mosnaim, G.S., Lee, T.Y. and Johnson, K.M., 2024. Cost-effectiveness of budesonide-formoterol vs inhaled epinephrine in US adults with mild asthma. *Annals of Allergy, Asthma & Immunology*, 132(2), pp.229-239.
- Hsu, E., & Bajaj, T. 2019. Beta 2 agonists.
- Kalola, U. K., & Ambati, S. 2020. Budesnide.
- [Kemenkes] Kementrian Kesehatan Republik Indonesia. 2013. Pedoman Penerapan Kajian Farmakoekonomi.
- [Kemenkes] Kementrian Kesehatan Republik Indoneisa. 2013. PEDOMAN NASIONAL PELAYANAN KEDOKTERAN TATA LAKSANA PENYAKIT PARU OBSTRUKTIF KRONIK
- Liao, P.A., Pan, S.W., Chen, C.Y., Deng, C.Y. and Dong, Y.H., 2023. Prescription patterns of new use of fixed-dose combination inhalers in patients with chronic obstructive pulmonary disease: long-acting β 2 agonists plus long-acting muscarinic antagonists

versus long-acting β_2 agonists plus inhaled corticosteroids. International Journal of Chronic Obstructive Pulmonary Disease, pp.553-563.

Lorensia, A., Puspitasari, M. D., Soedarsono, S., & Suryadinata, R. V. 2022. Cost-Effectiveness Analysis of Budesonide/Formoterol and Fluticasone/Salmeterol for Stable Chronic Obstructive Lung Disease. *Jurnal Respirologi Indonesia (JRI)*, 42(4), 289-297.

Miravittles, M., Worth, H., Soler Cataluña, J. J., Price, D., De Benedetto, F., Roche, N., & Ribera, A. 2014. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. *Respiratory research*, 15, 1-13.

Murgia, N. and Gamberale, A., 2022. Occupational COPD—The most under-recognized occupational lung disease?. *Respirology*, 27(6), pp.399-410.

Müllerová, H., Lu, C., Li, H., & Tabberer, M. 2014. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. *PloS one*, 9(1), e85540.

[PDPI] Perhimpunan Dokter Paru Indonesia. 2021. Panduan Umum Praktik Klinis Penyakit Paru dan Pernapasan.

[PDPI] Perhimpunan Dokter Paru Indonesia 2023. Penyakit Paru Obstruktif. *Panduan Umum Praktik Klinis Penyakit Paru dan Pernapasan*.

Phillips, D. B., Elbehairy, A. F., James, M. D., Vincent, S. G., Milne, K. M., De-Torres, J. P., ... & O'Donnell, D. E. 2022. Impaired ventilatory efficiency, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease: results from the CanCOLD study. *American Journal of Respiratory and Critical Care Medicine*, 205(12), 1391-1402.

Qian, C.J., Coulombe, J., Suissa, S. and Ernst, P., 2017. Pneumonia risk in asthma patients using inhaled corticosteroids: a quasi-cohort study. *British journal of clinical pharmacology*, 83(9), pp.2077-2086.

Rahmandani, A., Sarnianto, P., Anggriani, Y. and Purba, F.D., 2021. Analisis efektivitas biaya penggunaan obat antivirus Oseltamivir dan Favipiravir pada pasien Covid-19 derajat sedang di Rumah Sakit Sentra Medika Cisalak Depok. *Majalah Farmasetika*, 6, pp.133-144.

Rai, M., & Goyal, R. 2018. Pharmacoeconomics in healthcare. In *Pharmaceutical medicine and translational clinical research* (pp. 465-472). Academic Press.

Remien, K., & Bowman, A. 2019. Fluticasone.

Ritoga, H.O. 2018. ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN INHALASI BUDESONID/FORMOTEROL DIBANDINGKAN DENGAN INHALASI FLUTIKASON/SALMETEROL PADA PASIEN PENYAKIT PARU OBSTRUksi

KRONIK (PPOK) RAWAT JALAN DI RUMAH SAKIT PARU RESPIRA YOGYAKARTA.

- Rodrigo, G. J., Price, D., Anzueto, A., Singh, D., Altman, P., Bader, G., ... & Kostikas, K. 2017. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. *International journal of chronic obstructive pulmonary disease*, 907-922.
- Sadatsafavi, M., FitzGerald, J.M., O'Byrne, P.M., Soliman, M., Sriskandarajah, N., Vicente, C. and Golam, S.M., 2021. The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada. *Allergy, Asthma & Clinical Immunology*, 17, pp.1-13.
- Sari, C. P., Hanifah, S., Rosdiana, R., & Anisa, Y. 2021. Efektivitas Pengobatan pada Pasien Penyakit Paru Obstruksi Kronis (PPOK) di Rumah Sakit Wilayah Yogyakarta. *Jurnal Manajemen Dan Pelayanan Farmasi (Journal Of Management And Pharmacy Practice)*, 11(4), 215.
- Shin, H. J., Kim, Y. I., Kim, Y., Lee, C. Y., Ra, S. W., Moon, J. Y., ... & KOCOSS Cohort Study Group. 2023. When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?. *Chonnam Medical Journal*, 59(3), 180.
- Suggett, J., Kushnarev, V. and Sadafi, H., 2022. Dry Powder Inhalers (DPIs) vs Metered Dose Inhaler (MDI) with valved spacer: Using Functional Respiratory Imaging (FRI) to assess modelled lung deposition in a COPD patient.
- Tashkin, D. P. 2020. Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease. *International Journal of Chronic Obstructive Pulmonary Disease*, 3105-3122.
- Tonin, F. S., Leonart, L. P., & Casas, C. 2023. Pharmacoeconomic Analysis Methods. In *Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy* (pp. 1057-1074). Cham: Springer International Publishing.
- Velayati, A., Hosseini, S.A., Sari, A.A., Mohtasham, F., Ghanei, M., Yaghoubi, M. and Majdzadeh, R., 2015. Comparison of the effectiveness and safety of formoterol versus salmeterol in the treatment of patients with asthma: A systematic review and meta-analysis. *Journal of Research in Medical Sciences*, 20(5), pp.483-490.
- [WHO] World Health Organization. 2017. Global status report on noncommunicable diseases 2017. World Health, 176.
- [WHO] World Health Organization 2022. Noncommunicable diseases, dari: <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases.,> diakses pada tanggal 28 Januari 2024
- [WHO] World Health Organization. 2020. The top 10 causes of death, dari : <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>

Wu, Z., Bian, X., Hui, L. and Zhang, J., 2020. Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study Corrigendum in/10.3892/etm. 2020.9140. *Experimental and therapeutic medicine*, 19(3), pp.1665-1672.

Ye, Q., He, X. O., & D'Urzo, A. 2017. A review on the safety and efficacy of inhaled corticosteroids in the management of asthma. *Pulmonary Therapy*, 3, 1-18.